GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Retail - Defensive » X Bioscience PCL (BKK:XBIO-W7) » Definitions » Capex-to-Operating-Cash-Flow

X Bioscience PCL (BKK:XBIO-W7) Capex-to-Operating-Cash-Flow : 0.00 (As of Mar. 2025)


View and export this data going back to 2025. Start your Free Trial

What is X Bioscience PCL Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

X Bioscience PCL's Capital Expenditure for the three months ended in Mar. 2025 was ฿-1.11 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2025 was ฿-16.60 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


X Bioscience PCL Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for X Bioscience PCL's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

X Bioscience PCL Capex-to-Operating-Cash-Flow Chart

X Bioscience PCL Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

X Bioscience PCL Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of X Bioscience PCL's Capex-to-Operating-Cash-Flow

For the Food Distribution subindustry, X Bioscience PCL's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


X Bioscience PCL's Capex-to-Operating-Cash-Flow Distribution in the Retail - Defensive Industry

For the Retail - Defensive industry and Consumer Defensive sector, X Bioscience PCL's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where X Bioscience PCL's Capex-to-Operating-Cash-Flow falls into.


;
;

X Bioscience PCL Capex-to-Operating-Cash-Flow Calculation

X Bioscience PCL's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-36.328) / -37.444
=N/A

X Bioscience PCL's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-1.105) / -16.596
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


X Bioscience PCL  (BKK:XBIO-W7) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


X Bioscience PCL Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of X Bioscience PCL's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


X Bioscience PCL Business Description

Traded in Other Exchanges
Address
Phahon Yothin Road, No.304, Room No.1803-1806, 18th Floor, Vanit Place Aree Tower (Tower A, Sam Sen Nai, Bangkok, THA, 10400
X Bioscience PCL is engaged in investment in food and beverages business and the group are engaged in selling food and beverages, and manufacturing and selling biological products. The group operates in two business segments: the food and beverage sales segment and the internal management services segment provided by the parent company. The group operates in a single geographic area, which is Thailand. The company's brand consists of Kagonaya, Bake, and Leboeuf.

X Bioscience PCL Headlines

No Headlines